.Nature Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view calls for introduction of individuals along with MASLD and also size of liver outcomes in cardio-- kidney-- metabolic tests, when records suggest mechanistically plausible advantages and professional protection-- and details factors for trial layout as well as governing approval.